Showing results (11-20 of 19) with videos related to
Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Pharmaceutical Research|August 11, 2001
Divergent effects of raloxifene HCI on the pharmacokinetics and pharmacodynamics of warfarinJ W Miller, A Skerjanec, M P Knadler, et al.Clinical Pharmacology and Therapeutics|November 1, 1987
Absorption studies of the H2-blocker nizatidineM P Knadler, R F Bergstrom, J T Callaghan, et al.Journal of Pharmaceutical Sciences|January 1, 1985
Stereoselective inversion of (R)-fenoprofen to (S)-fenoprofen in humansA Rubin, M P Knadler, P P Ho, et al.Clinical Endocrinology|February 15, 2000
Raloxifene reduces atherosclerosis: studies of optimized raloxifene doses in ovariectomized, cholesterol-fed rabbitsN H Bjarnason, J Haarbo, I Byrjalsen, et al.International Journal of Clinical Pharmacology and Therapeutics|February 25, 2005
Duloxetine pharmacokinetics in cirrhotics compared with healthy subjectsA Suri, S Reddy, C Gonzales, et al.Clinical Pharmacology and Therapeutics|June 1, 1990
Secretion of nizatidine into human breast milk after single and multiple dosesB D Obermeyer, R F Bergstrom, J T Callaghan, et al.Drug Metabolism and Disposition: the Biological Fate of Chemicals|August 16, 2003
Metabolism, excretion, and pharmacokinetics of duloxetine in healthy human subjectsR J Lantz, T A Gillespie, T J Rash, et al.Scandinavian Journal of Gastroenterology. Supplement|January 1, 1987
A pharmacokinetic profile of nizatidine in manJ T Callaghan, R F Bergstrom, A Rubin, et al.Diabetes, Obesity & Metabolism|October 11, 2016
Reduced peripheral activity leading to hepato-preferential action of basal insulin peglispro compared with insulin glargine in patients with type 1 diabetesS Mudaliar, R R Henry, T P Ciaraldi, et al.Pageof 2